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ABSTRACT
The hypomethylating agents (HMAs) are standard therapy for patients with 
higher-risk myelodysplastic syndrome (MDS); however, the majority of the patients 
will lose their response to HMAs over time due to unknown mechanisms. It has recently 
been shown that T cell expression of the immunoinhibitory receptor PD-1 is regulated 
by DNA methylation. In 12 of 27 patients (44%) PD-1 promoter demethylation 
was observed in sorted peripheral blood T cells isolated over consecutive cycles of 
treatment with 5-azacytidine (5-aza). The PD-1 promoter demethylation correlated 
with an increase in PD-1 expression. Moreover, demethylation of the PD-1 promoter 
correlated with a significantly worse overall response rate (8% vs. 60%, p = 0.014), 
and a trend towards a shorter overall survival (p = 0.11) was observed. A significantly 
higher baseline methylation level of the PD-1 promoter was observed in T cells of 
non-responding patients compared to healthy controls (p = 0.023).
Accordingly, in addition to their beneficial function, HMAs induce PD-1 expression 
on T cells in the MDS microenvironment, thereby likely hampering the immune 
response against the MDS blasts. Thus, we suggest that activation of the PD-1 
checkpoint during HMA treatment can be a possible resistance mechanism, which 
may be overcome by combination therapy with a PD-1 pathway inhibitor.
INTRODUCTION
Myelodysplastic syndromes (MDS) are clonal 
hematopoietic stem cell disorders, characterized by 
increased proliferation and aberrant differentiation 
combined with a high rate of apoptosis [1]. This results in 
ineffective hematopoiesis and peripheral blood cytopenias 
as well as an increased risk of developing acute myeloid 
leukemia (AML). Compared to conventional care 
regimens, hypomethylating agents (HMAs) have resulted 
in improved outcomes in MDS [2–4], including delayed 
leukemic transformation [4] and prolonged survival 
in patients with higher-risk MDS [2]. 5-azacytidine 
(5-aza) treatment has also prolonged overall survival (OS) 
in patients with AML with 20–30% bone marrow blasts 
[5], and decitabine (5-aza-2’deoxycytidine) has improved 
the response rates in older patients (> 65 yrs) with 
newly diagnosed AML [6]. In addition, HMAs are also 
approved by the U.S Food and Drug Administration and 
the European Medicines Agency for treatment of chronic 
myelomonocytic leukemia (CMML). Still, only about 50% 
of the HMA treated patients achieve a clinical response, the 
majority will lose response over time [2], and the outcome 
after HMA failure is poor with a median survival of only 
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5.6 months [7]. Consequently, there is an urgent need for 
efficient new treatment modalities in MDS.
The molecular mechanisms of action of HMAs 
are currently not completely understood. Reactivation of 
silenced tumor suppressor genes has been suggested to be 
a key event [8]; however, others and we have also shown 
that HMAs induce the expression of tumor antigens such 
as cancer testis antigens (CTAs) on the malignant cells [9, 
10]. Since CTAs are normally only expressed at immune 
privileged sites, e.g. in testicular germ cells, expression 
of CTAs by the MDS blasts can stimulate an anti-tumor 
immune response by induction of effector T cells of 
the adaptive immune system [11–13]. By contrast, the 
mechanisms of resistance to HMAs are largely unknown.
The programmed death-1 (PD-1) is an immuno-
inhibitory receptor mainly expressed on activated T cells 
[14]. Two ligands for PD-1 are currently known, PD-L1 
(B7-H1) and PD-L2 (B7-DC). Under normal circumstances 
both ligands are expressed in low levels in a wide variety 
of cell types, but surface expression of the protein is rare 
[15]. The major role of PD-1 is to limit T cell effector 
responses in peripheral tissues in relation to infection 
and inflammation, and to limit autoimmunity [14, 16]. In 
addition, the PD-1/PD-L1 pathway plays an important role 
in tumor immune evasion and growth [17]. Interestingly, it 
was recently shown that expression of PD-1 on T cells is 
regulated by DNA methylation [18]. Hypomethylation of the 
PD-1 promoter was observed in CD8+ T cells with inhibited 
function, referred to as exhausted T cells. Interestingly, in 
vitro studies showed that treatment with an HMA increases 
the expression of PD-1 on activated T cells [18].
PD-L1 and, to a lesser extent, PD-L2 are overexpressed 
in various types of human tumors, including hematological 
malignancies such as MDS and AML [19–23]. An increasing 
amount of data indicate that interactions between PD-1 and 
its ligands are important mechanisms of immune suppression 
in the tumor microenvironment [15, 19, 20].
The objective of this study was to investigate the in 
vivo effect of HMA on PD-1 methylation and expression 
in T cells obtained from patients during 5-aza treatment, 
and to evaluate the rationale of combining HMA with a 
PD-1 pathway inhibitor in MDS.
RESULTS
PD-1 methylation in healthy individuals
First, we evaluated the level of PD-1 promoter 
methylation in peripheral blood mononuclear cells 
(PBMNCs), granulocytes, CD3+ T cells, CD4+ T cells, 
CD8+ T cells, and CD19+ B cells from five healthy 
donors (Figure 1). The mean PD-1 methylation level was: 
PBMNCs 37.2% (range 24.9–58.7), granulocytes 60.1% 
(range 47.3–77.5), CD3+ T cells 20.2% (range, 9.7–33.2), 
CD4+ T cells 24.9% (range 11.6–38.5), CD8+ T cells 
24.0% (range 12.8–46.0) and CD19+ B cells 43.3% (range 
Figure 1: Mean PD-1 promoter methylation in six distinct cell populations from 5 healthy donors. All cells are from 
peripheral blood. The graph shows the means. PBMNC = peripheral blood mononuclear cells. CD3 = CD3+ T cells. CD4 = CD4+ T cells. 
CD8 = CD8+ T cells. Gran = granulocytes. B cells = CD19+ B cells.
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31.5–67.3). The analyses revealed a varying methylation 
level both among the different cell types and donors. The T 
cell population carried the lowest level of PD-1 promoter 
methylation, which is in line with the fact that the highest 
PD-1 gene expression is observed in T cells.
PD-1 methylation in peripheral blood 
mononuclear cells from 5-aza treated patients
Next, we investigated the status of PD-1 promoter 
methylation in PBMNCs sampled from patients during the 
course of 5-aza treatment. Initially, we analyzed unsorted 
PBMNCs from 15 (12 MDS, 1 AML and 2 CMML) 5-aza 
treated patients (patient characteristics, see Table 1). 
Samples from day one and day five of each treatment 
cycle were analyzed. The patients had received a median 
number of four cycles of 5-aza (range 2–13). A total of 121 
peripheral blood (PB) samples were analyzed. Nine of 15 
(60%) patients demonstrated a significant decrease in PD-1 
promoter methylation after 5-aza administration compared 
to the pre-treatment level (Figure 2A). Demethylation was 
defined relative to the baseline methylation level based on 
the following criteria: A statistically significant decrease 
in methylation level and a decrease of ≥ 10%-points. The 
demethylation should furthermore occur in ≥ 2 distinct 
treatment cycles.
We observed that the baseline level as well as the 
continuous level of PD-1 promoter methylation varied 
among the patients during 5-aza treatment with different 
methylation patterns over time. In nine patients PD-1 
promoter demethylation was observed, mostly followed 
by a diverse remethylation just before the start of the next 
cycle. In the remaining six patients a stable methylation 
level, or a slight gain in methylation, was seen throughout 
the entire treatment period (Figure 2B). The mean baseline 
methylation level was significantly higher in the group 
of patients in whom we observed a demethylation of the 
PD-1 promoter, 57.0% (SD, 16.2) vs. 30.4% (SD, 15.0), 
p = 0.007, 95%-CI [8.7;44.5]. Taken together, these results 
reveal that 5-aza does demethylate the PD-1 promoter in 
patients PBMNCs in vivo.
PD-1 promoter methylation in CD4+ and CD8+ 
T cells from 5-aza treated patients
Since the observed changes in methylation level 
in PBMNCs could either be a result of a real change in 
methylation or simply a result of an alteration in the 
composition of the mononuclear cell subpopulations, we 
extended our analyses to include isolated T lymphocyte 
subsets. In 22 (15 MDS, 4 AML, 3 CMML, patient 
characteristics see Table 1) of the 27 patients we 
Table 1: Patient characteristics RA = refractory anemia. RCMD = refractory cytopenias with 
multilineage dysplasia. RAEB = refractory anemia with excess blasts. AML = acute myeloid leukemia. 
CMML = chronic myelomonocytic leukemia. IPSS = international prognostic scoring system. IWG = 
International Working Group. CR = complete remission. 5-aza = 5-azacytidine.
All PD-1 demethylation No PD-1 
demethylation
p value
N 27 12 (44%) 15 (56%)
Age median (range) 65 (46–82) 67 (52–82) 66 (46–77) .79
Sex
 Male 14 6 8 .86
 Female 13 6 7
WHO diagnosis
 RA 2 0 2 .49
 RCMD 3 1 2 1
 RAEB-1 2 0 2 .49
 RAEB-2 12 6 6 .60
 AML 5 4 1 .14
 CMML-2 3 1 2 1
IPSS
 Low 0 0 0 -
 Int-1 7 1 6 .091
(Continued )
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investigated the PD-1 promoter methylation in sorted 
CD4+ and CD8+ T cells. PD-1 promoter methylation was 
examined in both CD8+ T cells and CD4+ T cells because of 
their cooperative function in tumor surveillance. Ten of the 
22 patients were also included in the analyses of PBMNCs 
described above.
The 22 patients had received a median number of 
five courses of 5-aza (range 3–14). A total of 132 PB 
samples were sorted and analyzed. Nine (41%) of the 
patients demonstrated a significant decrease in PD-1 
promoter methylation in the T cell compartment after 5-aza 
administration (Figure 3A and 3B). In two of these patients 
we only observed demethylation in either the CD4+ T 
cells or the CD8+ T cells. In the remaining 13 patients an 
increase in PD-1 methylation or no methylation changes 
were observed (Figure 4A and 4B). The mean baseline 
methylation level in T cells was significantly higher in the 
group of patients in whom we observed a demethylation 
of the PD-1 promoter, both compared to patients where no 
demethylation were observed (48.0% (SD 15.8) vs. 25.7% 
(SD 9.4) (p < .001, 95%-CI [13.1;31.5]), and compared 
to healthy donors (48.0% (SD 15.8) vs. 24.5% (SD 11.1) 
(p < .0001, 95%-CI [11.7;35.4])) (Figure 5). A trend 
towards higher PD-1 baseline methylation in the patients’ 
PBMNCs and T cells compared to those of healthy donors 
was observed (PBMNCs, p = 0.07; 95%-CI [−1.7;38.2] , 
T cells, p = 0.16; 95%-CI [−3.0;17.7]).
Comparison of the methylation levels in PBMNCs 
and T cells from the 10 patients, where data on both cell 
types were available, reveals a difference in the baseline 
levels as well as a difference during treatment. In six of 
the ten patients we observed a good correlation between 
the relative methylation level in PBMNCs and T cells 
during treatment, either occurring as demethylation 
or no demethylation in both cell populations. In one 
patient we observed a demethylation in PBMNCs 
and CD4+ T cells but not in CD8+ T cells, and in three 
patients demethylation was seen in the compound 
PBMNC population; however, no demethylation was 
observed in the T cells at the corresponding time points 
(Supplementary Figure 1). Accordingly, changes in PD-1 
methylation in PBMNCs do not always reflect the changes 
in the T cell compartment, emphasizing the importance of 
analyzing sorted cells.
All PD-1 demethylation No PD-1 
demethylation
p value
 Int-2 9 6 3 .13
 High 9 4 5 1
 AML (>30% blasts) 1 1 0 -
 Missing 1 0 1 -
Cytogenetics (IPSS)
 Good 8 2 6 .24
 Intermediate 10 4 6 1
 Poor 9 6 3 .11
Prior treatment 16 6 10 .45
 Chemotherapy 8 6 5
 Growth factor treatment 8 1 7
 No prior treatment 11 6 5
Time (months) from 
diagnosis until 5-aza-start 
median (range)
4 (0–37) 6.5 (0–11) 3 (0–37) .83
Median no. of cycles of 
5-aza 5 (2–14) 4 (2–13) 5 (3–14) .40
IWG 2006 Response
 CR 3 (11%) 1 (8%) 2 (13%) 1
 Overall response 10 (37%) 1 (8%) 9 (60%) .014
Overall survival (days) 
(median) 309 216 334 .11 (log rank)
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Figure 2: Dynamics of PD-1 promoter methylation in peripheral blood mononuclear cells of 15 patients during 
treatment with 5-azacytidine. (A) PD-1 promoter methylation in the 9 patients in whom we observed a classifiable demethylation. 
(B) PD-1 promoter methylation in the 6 patients in whom we did not observe a classifiable demethylation. C = course of 5-aza treatment.  
D = day in treatment course. PBMNC = peripheral blood mononuclear cells.
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Figure 3: Dynamics of PD-1 promoter methylation in peripheral blood CD4+ and CD8+ T cells from the patients with 
PD-1 promoter demethylation during treatment with 5-azacytidine. (A) PD-1 promoter methylation in CD4+ T cells of eight 
patients. (B) PD-1 promoter methylation in CD8+ T cells of eight patients. In patient no. 123 we only observed demethylation in the CD4+ 
T cells (CD8+ T cells from patient no. 123 are included in Figure 4B) and in patient no. 60 we only observed demethylation in the CD8+ T 
cells (CD4+ T cells from patient no. 60 are included in Figure 4A). C = course of 5-aza treatment. D = day in treatment course.
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Figure 4: Dynamics of PD-1 promoter methylation in peripheral blood CD4+ and CD8+ T cells from patients without 
PD-1 promoter demethylation during treatment with 5-azacytidine. (A) PD-1 promoter methylation in CD4+ T cells of 14 
patients. (B) PD-1 promoter methylation in CD8+ T cells of 14 patients. In patient no. 123 we observed demethylation in the CD4+ T cells 
(CD4+ T cells from patient no. 123 are included in Figure 3A) and in patient no. 60 we observed demethylation in the CD8+ T cells (CD8+ T 
cells from patient no. 60 are included in Figure 3A). C = course of 5-aza treatment. D = day in treatment course.
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Altogether, the methylation analyses revealed 
demethylation of the PD-1 promoter during 5-aza 
treatment in 12 of 27 (44%) patients.
PD-1 expression in CD4+ and CD8+ T cells from 
5-aza treated patients
To investigate whether demethylation of the 
PD-1 promoter during 5-aza treatment leads to an 
increased expression of PD-1, we examined the expression 
of PD-1 mRNA in the same cells before and during 5-aza 
treatment. The gene expression was examined in ten 
patients; PD-1 promoter demethylation in CD4+ and/
or CD8+ T cells correlated with an increase in PD-1 
expression. No PD-1 up-regulation was observed in the 
patients without demethylation of the PD-1 promoter.
Moreover, to support the correlation between 
increased PD-1 mRNA and cell surface protein 
expression, we performed multiparameter flow cytometry 
on PBMNCs from four patients by measuring the PD-1 
expression (median fluorescence intensity, MFI) on 
CD8+ T cells expressing the activating marker CD45RO 
(Figure 6). The two patients showing a PD-1 promoter 
demethylation and increase in PD-1 mRNA expression 
following 5-aza treatment markedly increased the PD-1 
protein surface expression level too, compared to the other 
two patients with no demethylation of the PD-1 promoter.
Correlation between methylation and expression 
in CD4+ and CD8+ T cells from 5-aza treated 
patients
Next we compared the PD-1 gene expression to the 
PD-1 promoter methylation levels in T cells from the ten 
patients where corresponding values of the parameters 
were available. We found a statistically significant inverse 
correlation between the PD-1 promoter methylation and 
expression level (p < 0.0001) (Figure 7).
Correlation between clinical response and PD-1 
promoter methylation
Due to PD-1’s inhibiting role on anti-tumor immune 
responses, we wanted to investigate whether demethylation 
Figure 5: Baseline PD-1 promoter methylation in peripheral blood CD4+ and CD8+ T cells from 5-azacytidine treated 
patients and five healthy donors. The patients are grouped according to whether the PD-1 promoter demethylates or not during 
treatment. The values for CD4+ and CD8- T cells are pooled.
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of the PD-1 promoter in T cells and PBMNCs during 5-aza 
treatment is correlated to the clinical response. A significant 
difference in overall response rate (ORR) was observed 
when comparing patients with and without PD-1 promoter 
demethylation (Table 1). In the group of patients with PD-
1 promoter demethylation, only one of 12 (8%) patients 
showed an overall response to 5-aza. Of the 15 patients 
with no demethylation an overall response was observed in 
9 patients (60%). The ORR was significantly higher in the 
group of patients without PD-1 promoter demethylation 
(p = 0.014). Furthermore, a trend towards longer OS was 
seen in the patients without PD-1 promoter demethylation 
(p = 0.11) (Supplementary Figure 2). Non-responding 
patients had a significantly higher baseline PD-1 promoter 
methylation compared to healthy controls (38.2% vs. 
24.5%; p = 0.023, 95%-CI [2.0;25.4]) and a trend towards 
a higher baseline PD-1 promoter methylation compared to 
responding patients (28.5% vs. 38.2%; p = 0.096, 95%-CI 
[-21.1;1.8]) (Figure 8). Taken together, these data indicate 
that demethylation of the PD-1 promoter in T cells during 
5-aza treatment might be associated with a poorer clinical 
response to 5-aza.
DISCUSSION
Treatment with HMAs has become the standard of 
care in higher-risk MDS patients who are not eligible for 
allogeneic hematopoietic stem cell transplantation, and is 
also approved for CMML and AML patients with 20–30% 
blasts. Even though the effects of single agent therapy with 
HMAs are encouraging, remissions are not long lasting, 
and novel treatment modalities are urgently needed in 
MDS. Within recent years immune modulating agents 
have shown promise as novel anti-cancer agents in both 
experimental and clinical studies in solid tumors [24, 25].
It was recently shown that up-regulation of the 
immune inhibitory receptor PD-1 on T cells during 
infections is coupled to demethylation of CpG sites in the 
PD-1 promoter [18]. During the development of T cells 
from naïve to activated and memory T cells, the PD-1 
promoter changes from methylated to unmethylated and 
back to methylated again. Under normal circumstances, 
demethylation of the PD-1 promoter appears to be 
mediated by ligation of the T cell receptor (TCR) [26]. 
Youngblood et al. showed that 5-aza was able to sustain 
Figure 6: PD-1 protein surface expression on CD8+ T cells from 5-aza treated patients. PD-1 protein surface expression, as 
expressed by the median fluorescence intensity (MFI), on CD8+/CD45RO+ T cells from PBMNCs of four patients at baseline before 5-aza 
treatment (1) and following the first treatment cycle (2) (the first available sample for every patient after the first treatment cycle. Patient no. 
94, 123, 141 and 146: C4D5, C3D1, C2D1 and C3D1, respectively (C = course of 5-aza treatment. D = day in treatment course)). In patient 
no. 94 and 141 an increase in PD-1 protein expression is observed (MFI: 770 to 853 (MFIR: 1.11), and MFI: 220 to 358 (MFIR: 1.63), 
respectively), whereas in patient no. 123 and 146 no increase is observed (MFI: 336 to 291 (MFIR: 0.89), and MFI: 426 to 373 (MFIR: 
0.88), respectively). Correspondingly, we observed a significant demethylation of the PD-1 promoter during treatment in CD8+ T cells in 
patient no. 94 and 141 (Figure 3B) and no demethylation in patient no. 123 and 146 (Figure 4B). Moreover, we saw a higher baseline MFI 
of PD-1 in patient 94 compared to patient 141, which is in line with the variation in baseline methylation level.
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a high expression of PD-1 mRNA and protein in vitro, 
indicating that DNA methylation causes PD-1 repression. 
Interestingly, during chronic infections, the PD-1 
promoter remains unmethylated with continuous PD-1 
overexpression in the chronically activated T cells, leading 
to exhausted and dysfunctional T cells [27]. Furthermore, 
it appears that persistent antigen expression by malignant 
tumors, like chronic infections, can promote the expression 
of inhibitory surface molecules on T cells, which can cause 
functional T cell exhaustion [28]. Our study suggests 
that 5-aza treatment may facilitate the exhaustion of 
tumor-specific T cells in patients and provides a possible 
explanation for the development of 5-aza resistance.
One recent study by Yang et al. has examined the 
effect of HMAs on PD-1 expression and methylation 
during the first treatment cycle. In a heterogeneous cohort 
of 61 patients (MDS, CMML and AML) treated with 
HMAs (the majority (87%) in combination with other 
agents) up-regulation (≥2-fold) of PD-1 gene expression 
in PBMNCs was observed during the first cycle of therapy 
in 58% of the patients. In a subgroup of 18 patients PD-1 
promoter methylation in PBMNCs was investigated, and 
the baseline methylation levels were higher in resistant 
patients as compared to responding patients – a trend also 
observed in the current study of sorted T cells. Moreover, 
Yang et al. observed that the methylation level during 
the first treatment course was more dynamic in resistant 
patients as compared to responding patients [22].
Here, we have demonstrated that in vivo treatment 
with 5-aza has direct impact on the expression of PD-1. 
Treatment with 5-aza was accompanied by a loss of DNA 
methylation in the PD-1 promoter in 44% (12 of 27) of 
the patients and the methylation level of the promoter was 
inversely correlated with PD-1 gene expression in T cells. 
Flow cytometry analyses of the PD-1 protein expression 
on CD8+ T cells supported the correlation between the 
Figure 7: Correlation between PD-1 promoter methylation and PD-1 gene expression in peripheral blood CD4+ 
and CD8+ T cells from 5-azacytidine treated patients. Ten patients and their corresponding values of methylation and relative 
expression before and during 5-aza treatment (altogether 117 pairs of observations). Methylation level is plotted as co-variate and the 
relative expression as outcome on a log-log scale with the base 2. The linear regression reveals a statistically significant inverse relationship 
between the two log-transformed variables (p < .0001) with the regression coefficient −2.0936 (SE 0.2521).
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increase in PD-1 mRNA and the expression of PD-1 cell 
surface protein. Our combined analyses of both PBMNCs 
and sorted T cells in ten patients revealed that the PD-1 
promoter methylation changes observed in the PBMNCs 
do not always reflect the methylation changes in the T 
cell population. This is probably due to changes in the 
composition of the PBMNCs rather than changes in the 
PD-1 promoter methylation, emphasizing the importance 
of sorting out the relevant cells in such studies.
Interestingly, we found a significantly higher 
ORR and a trend towards a better OS in patients without 
demethylation of the PD-1 promoter during 5-aza 
treatment. The baseline PD-1 methylation level was 
significantly higher in patients where a demethylation was 
observed, both compared to normal controls and to patients 
where no demethylation was observed. Furthermore, 
a significantly higher baseline PD-1 methylation level 
was observed in non-responding patients compared 
to healthy controls. In addition, we demonstrate that a 
clinical relevant PD-1 demethylation is not limited to the 
first treatment cycle but occurs throughout the treatment 
course. Accordingly, we believe that our study, on isolated 
T cell populations and with longer follow-up time, is an 
important extension to the initial findings of Yang et al.
A few studies indicate that PD-L1 and PD-L2 is 
overexpressed in higher-risk MDS [22, 23] and that PD-
L1 may also be induced by 5-aza treatment [29]. It has 
furthermore been shown that expression of PD-L1 is 
an independent negative prognostic factor in different 
malignancies [13, 15]. This relates to the fact that the PD-1/
PD-L1 pathway is a central mediator of T cell exhaustion (as 
well as inducer of T cell apoptosis [17]). Thus, expression of 
the PD-1 ligands on tumor cells appears to be an important 
way of evading the specific tumor immune response. Recent 
clinical trials with blockade of the PD-1 pathway have shown 
significant clinical responses in solid tumors [30, 31]. The 
flow cytometry data presented in this study together with 
previous in vitro and murine studies [18, 23, 32] indicate 
a positive correlation between PD-1 gene expression and 
surface expression in vivo; thus, we believe that the observed 
PD-1 demethylation and mRNA up-regulation lead to 
increased PD-1 surface expression on activated T cells.
Interestingly, we show that demethylation of the 
PD-1 promoter during 5-aza treatment correlates with a 
Figure 8: Baseline PD-1 promoter methylation in peripheral blood CD4+ and CD8+ T cells from 5-azacytidine treated 
patients and five healthy donors. The patients are grouped according to whether they responded or not responded to the treatment. 
The values for CD4+ and CD8- T cells are pooled.
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poorer ORR. This suggests that PD-1 up-regulation in T cells 
caused by 5-aza might be involved in the impaired response/
development of resistance to 5-aza treatment observed in a 
substantial fraction of patients. Obviously, our findings need 
validation in a larger and uniformly treated cohort. However, 
this study provides an important demonstration of 5-aza 
being able to up-regulate PD-1, a key immunoinhibitory 
receptor, in patients’ T cells in vivo. We believe that the 
observed effect of 5-aza on PD-1 may accelerate the 
development of dysfunctional effector T cells leading to 
primary or secondary resistance. We therefore suggest that 
combination therapy with a HMA and a PD-1 pathway 
inhibitor in the treatment of higher-risk MDS will release this 
“brake” on the tumor-specific T cells, potentially enhancing 
their function. A reinforced immune response against the 
malignant blasts may improve the clinical outcomes in MDS.
MATERIALS AND METHODS
Patients and treatment
Peripheral blood (PB) was sampled from 27 patients 
with MDS (n = 19), CMML (n = 3) and AML (n = 5) and 5 
healthy donors. The patient samples were collected at the 
Department of Hematology, Rigshospitalet, Copenhagen, 
and Aarhus University Hospital, Aarhus, between 2008 
and 2011. The study was approved by the Regional Ethical 
Committee. All patients had signed informed consent 
according to the Declaration of Helsinki. All patients were 
diagnosed according to the World Health Organization 
(WHO) criteria [33], and the International Prognostic 
Scoring System (IPSS) [34] was used to stratify the MDS 
patients into risk-groups. Seven patients were classified 
as IPSS intermediate-1; they all progressed before the 
initiation of 5-aza treatment. The patients were treated 
with 100 mg/m2 s.c. 5-aza (Vidaza, Celgene, NJ) for five 
consecutive days in each 28-day cycle, according to the 
Nordic MDS guidelines (http://www.nmds.org/Nordic-
Care-Programme). PB samples were collected from each 
patient before 5-aza administration on day one and day 
five in each individual course of 5-aza treatment.
The clinical response to treatment was evaluated in 
accordance with the revised International Working Group 
(IWG) response criteria [35]. Overall response was defined 
as complete remission (CR), partial remission (PR), 
marrow CR with hematologic improvement (HI) and stable 
disease (SD) with HI. CR in the bone marrow without HI 
and SD without HI were defined as no response.
Patient characteristics and response to treatment are 
summarized in Table 1.
Isolation of mononuclear cells and sorting of 
CD4+ and CD8+ T cells
Peripheral blood mononuclear cells (PBMNCs) were 
isolated from peripheral blood immediately after sampling 
by using Ficoll-Paque PLUS (GE Healthcare) density-
gradient centrifugation and thereafter cryopreserved 
at ~-196°C for later use. The frozen PBMNCs were 
thawed and thereafter immediately separated into CD4+ 
and CD8+ T cells using magnetic bead-based separation 
on a RoboSep device according to the manufacturer’s 
instructions (StemCell Technologies). Separation of cell 
subsets from the healthy donors was performed on freshly 
isolated PBMNCs.
Nucleic acid extraction
Genomic DNA from MNCs was isolated using 
Gentra Puregene Cell Kit (Qiagen). Genomic DNA 
and total RNA from separated CD4+ and CD8+ T cells 
were extracted using the AllPrep DNA/RNA/miRNA 
Universal Kit (Qiagen) according to the manufacturer’s 
protocol. The DNA and RNA quantity and quality 
were controlled on a spectrophotometer (Eppendorf 
BioPhotometer).
Bisulfite conversion and pyrosequencing
250 ng of genomic DNA was bisulfite converted 
using the EZ DNA Methylation kit (Zymo Research) with 
a slight modification. Samples were incubated at 42°C for 
30 minutes instead of 37°C for 15 minutes. For the bisulfite 
reaction the alternative incubation conditions described in 
the appendix were used. The bisulfite-treated DNA was 
amplified by performing polymerase chain reaction (PCR) 
with locus-specific primers for the PD-1 gene promoter 
using PyroMark Gold master mix. Forward primer: 
5′-TTTGTGGATGGTTTTATATTATGGTTATAG-3′. 
Reverse primer: 5′-biotin-TCACAACCAACCCCTACC-3′. 
The PCR was performed on the Gene PCR System 9700 
(Applied Biosystems). PCR cycling conditions were 
as follows: One cycle of 95°C for 15 min, followed 
by 45 cycles of 94°C for 20 s, 60°C for 20 s and 72°C 
for 20 s, and one cycle of 72°C for 10 min. Methylation 
analysis was done by pyrosequencing of the PD-1 
promoter carried out on a PyroMark Q24 (Qiagen) using 
the PyroMark Gold Q24 reagents (Qiagen), according 
to the manufacturer’s instructions. Sequencing primer: 
5′-ATTATGGTTATAGTTTTAGATTTTT-3′. The design of 
the pyrosequencing assay was based on a former publication 
[18]. The assay covers three CpG-sites in the upstream 
DNA-sequence of the transcriptional start site of the PD-1 
gene (Supplementary Figure 3) [18]. The PD-1 methylation 
level for a given sample was calculated as a mean of the 
methylation % of the three investigated CpG-sites.
Real-time quantitative polymerase chain 
reaction
250 ng of total RNA was used for reverse transcrip-
tion reactions to generate cDNA using SuperScript III 
Reverse Transcriptase and random hexamer primers 
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(Invitrogen). Real-time quantitative PCR (RT-qPCR) of 
the PD-1 cDNA was performed using TaqMan assays 
(id. Hs01550088_m1, Applied Biosystems) [36]. The 
amplification was performed on a LightCycler 480 II 
instrument. The amplification curves were analyzed 
using Roche LightCycler version 1.5.1.62 software 
for determination of crossing point (Cp, by the second 
derivative method). All RT-qPCR assays were carried out 
in duplicate and then repeated with new cDNA synthesis. 
Reverse transcriptase negative cDNA synthesis reactions 
were performed for at least one sample per plate. Gene 
expression was normalized to endogenous GAPDH 
(TaqMan assay, id. Hs99999905_m1) expression and 
relative gene expression was calculated by using the 
comparative threshold method (2-∆∆CT method [37]) 
normalized to cDNA from T cells from the same patient at 
baseline of 5-aza treatment.
Flow cytometry
Cryopreserved PBMNCs were thawed, incubated 
with an Fc receptor blocking reagent (ChromPure Mouse 
IgG, Jackson ImmunoResearch Suffolk, UK) to inhibit 
non-specific binding before incubated with the following, 
pre-titrated antibodies (all from BD Biosciences, San Jose, 
CA): anti-CD3 V450, anti-CD45RO FITC, anti-PD-1 
(CD279) PE, and anti-CD8 AF700. Flow cytometry was 
acquired by a LSRFortessa (BD Biosciences, San Diego, 
CA) and data analyzed using FlowJo version 10.2 (Tree 
Star Inc., Ashland, OR). Compensation was performed 
using BD CompBeads (BD Biosciences). Applying gating 
strategies based on unstained controls and for PD-1 
the fluorescence minus one (FMO), the expression of 
PD-1 was measured on CD3+/CD45RO+/CD8+ singlets 
and given by the median fluorescense intensity (MFI) 
(Supplementary Figure 4).
Statistical analysis
Differences in clinical characteristics for patients 
with or without demethylation of the PD-1 promoter 
during 5-aza treatment were compared using the Pearson 
chi-squared test, or Fischer’s exact test if appropriate, 
for categorical variables and the Wilcoxon rank sum 
test for continuous variables. Overall survival was 
analyzed by the Kaplan-Meier method and compared 
using the log-rank test. Survival was measured from the 
onset of 5-aza therapy. Patients who were alive were 
censored at the date of last follow-up. Patients who 
underwent BM transplantation were censored at the day 
of transplantation. Statistically significant changes in gene 
promoter methylation were assessed by a linear mixed 
model (a three-level model) because of the correlation 
of within-patient measurements. Regression analysis of 
the association of gene promoter methylation and gene 
expression was calculated using mixed models due to the 
occurrence of repeated measurements. The mixed model 
analyses were performed using the SAS Enterprise Guide 
4.3 (SAS Institute, NC). All other statistical analyses 
were performed using SPSS version 22.0.0 (IBM, NY). 
Significance level was 5% and two-sided for all analyses.
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